Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx Inc. has demonstrated a solid revenue trajectory, with an 18% year-over-year increase leading to a combined revenue projection of $483 million, while guiding for significant growth towards $1 billion in peak sales by 2029. The company anticipates generating between $110 million and $120 million in revenue from XPHOZAH for FY26, fueled by enhanced clinical conviction and increased prescription volumes, particularly in the non-Medicare segments where dispensations have shown impressive growth of 41%. Furthermore, the ongoing Phase 3 trial for IBSRELA and continued expansion in prescribing practices are expected to bolster revenue-generating prospects, suggesting a sustained positive outlook for Ardelyx's overall financial performance.

Ardelyx Inc faces significant challenges that contribute to an unfavorable outlook, particularly highlighted by the anticipated 18% quarter-over-quarter decline in Ibsrela revenue for 1Q26, despite projections of total fiscal year revenue reaching $422 million. The company has also experienced a decrease in gross-to-net (GTN) margin, dropping from 31% to 30.2%, indicating potential pricing pressures that could negatively affect future profitability. Additionally, critical risks include the possibility of underwhelming commercial performance of Ibsrela relative to peak sales expectations and the potential impact of reimbursement pricing structure changes on the adoption of Ardelyx's products, which complicate the company's growth trajectory.